drugset / Trial / NCT02693236
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells(DC) combined with cytokine-induced killer (CIK) cells in patients with advanced esophagus cancer. Experimental recombinant adenovirus coded mRNA including MUC1 and Survivin that transfected DC, which are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the researcher plan to perform the clinical trial.
Timeline
- Start
- 2014-08
- Primary completion
- 2016-08
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | — | — |
| Subject | adenovirus-transfected autologous DC vaccine | Cell therapy | — | — |